Literature DB >> 16166346

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells.

Norihisa Ishimura1, Hajime Isomoto, Steven F Bronk, Gregory J Gores.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent for cancer therapy; however, many cholangiocarcinoma cells are resistant to TRAIL-mediated apoptosis. Resistance to apoptosis may unmask TRAIL signaling cascades favoring tumor biology. Thus our aim was to examine whether TRAIL is expressed by human cholangiocarcinomas, and if so, to determine whether it promotes a malignant phenotype. To address this objective, TRAIL expression in human liver specimens was evaluated by immunohistochemistry. The effect of TRAIL on tumor cell migration, invasion, and proliferation was examined in three human cholangiocarcinoma cell lines. TRAIL expression was upregulated by cholangiocytes in preneoplastic disease, primary sclerosing cholangitis, and human cholangiocarcinoma specimens. TRAIL promoted tumor cell migration and invasion but did not induce cell proliferation. TRAIL-mediated cell migration and invasion was NF-kappaB dependent. These data demonstrate that TRAIL promotes cell migration and invasion via a NF-kappaB-dependent pathway in human cholangiocarcinoma cell lines, an observation that has a potential negative implication for TRAIL in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166346     DOI: 10.1152/ajpgi.00242.2005

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  67 in total

1.  Targeting PDGFR-β in Cholangiocarcinoma.

Authors:  Christian D Fingas; Joachim C Mertens; Nataliya Razumilava; Steven F Bronk; Alphonse E Sirica; Gregory J Gores
Journal:  Liver Int       Date:  2011-12-02       Impact factor: 5.828

2.  The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.

Authors:  Francesco Carinci; Lorenzo Monasta; Corrado Rubini; Daniela Stramazzotti; Annalisa Palmieri; Elisabetta Melloni; Alex Knowles; Luca Ronfani; Giorgio Zauli; Paola Secchiero
Journal:  Invest New Drugs       Date:  2010-11-18       Impact factor: 3.850

3.  miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma.

Authors:  Nataliya Razumilava; Steve F Bronk; Rory L Smoot; Christian D Fingas; Nathan W Werneburg; Lewis R Roberts; Justin L Mott
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

4.  Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.

Authors:  Vera Levina; Adele M Marrangoni; Richard DeMarco; Elieser Gorelik; Anna E Lokshin
Journal:  Exp Cell Res       Date:  2008-01-16       Impact factor: 3.905

Review 5.  Life and death by death receptors.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

6.  Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer.

Authors:  Tobias Kiesslich; Christian Mayr; Julia Wachter; Doris Bach; Julia Fuereder; Andrej Wagner; Beate Alinger; Martin Pichler; Pietro Di Fazio; Matthias Ocker; Frieder Berr; Daniel Neureiter
Journal:  Mol Cell Biochem       Date:  2014-07-27       Impact factor: 3.396

7.  Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern.

Authors:  Ozlem Darcansoy Işeri; Meltem Demirel Kars; Ufuk Gündüz
Journal:  Mol Biol Rep       Date:  2011-07-01       Impact factor: 2.316

Review 8.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

9.  Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.

Authors:  Joachim C Mertens; Christian D Fingas; John D Christensen; Rory L Smoot; Steven F Bronk; Nathan W Werneburg; Michael P Gustafson; Allan B Dietz; Lewis R Roberts; Alphonse E Sirica; Gregory J Gores
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

10.  Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.

Authors:  Kazuyoshi Takeda; Yuko Kojima; Kenichi Ikejima; Kenichi Harada; Shunhei Yamashina; Kyoko Okumura; Tomonori Aoyama; Steffen Frese; Hiroko Ikeda; Nicole M Haynes; Erika Cretney; Hideo Yagita; Noriyoshi Sueyoshi; Nobuhiro Sato; Yasuni Nakanuma; Mark J Smyth; Ko Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.